Skip to main content
Start of main content

Early Changes in Waivered Clinicians and Utilization of Buprenorphine for Opioid Use Disorder After Implementation of the 2021 HHS Buprenorphine Practice Guidelines / U.S. Department of Health and Human Services ; Prepared by the Office of the Assistant Secretary for Planning and Evaluation